Evaluation on Inter-Assay Consistency and Inter-Reader Precision for PD-L1 Assays: Ventana SP263 and Dako 22C3 in Non-Small Cell Lung Cancer

被引:1
|
作者
Lin, D. [1 ]
Yang, X. [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Pathol,Minist Educ, Beijing, Peoples R China
关键词
PD-L1; Assays; TPS; Non-Small Cell Lung Cancer;
D O I
10.1016/j.jtho.2019.08.1663
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P2.09-14
引用
收藏
页码:S774 / S774
页数:1
相关论文
共 50 条
  • [21] Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
    Zhou, Caicun
    Srivastava, Minu K.
    Xu, Hao
    Felip, Enriqueta
    Wakelee, Heather
    Altorki, Nasser
    Reck, Martin
    Liersch, Rudiger
    Kryzhanivska, Anna
    Oizumi, Satoshi
    Tanaka, Hiroshi
    Hamm, John
    McCune, Steven L.
    Bennett, Elizabeth
    Gitlitz, Barbara
    McNally, Virginia
    Ballinger, Marcus
    McCleland, Mark
    Zou, Wei
    Das Thakur, Meghna
    Novello, Silvia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [22] Clinical impact of 22C3 PD-L1 expression in non-small cell lung cancer.
    Okabe, Naoyuki
    Takagi, Hironori
    Suzuki, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [23] Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
    Haipeng Xu
    Gen Lin
    Cheng Huang
    Weifeng Zhu
    Qian Miao
    Xirong Fan
    Biao Wu
    Xiaobing Zheng
    Xiandong Lin
    Kan Jiang
    Dan Hu
    Chao Li
    Scientific Reports, 7
  • [24] Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
    Xu, Haipeng
    Lin, Gen
    Huang, Cheng
    Zhu, Weifeng
    Miao, Qian
    Fan, Xirong
    Wu, Biao
    Zheng, Xiaobing
    Lin, Xiandong
    Jiang, Kan
    Hu, Dan
    Li, Chao
    SCIENTIFIC REPORTS, 2017, 7
  • [25] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
    Wilberger, Adam
    Aisner, Dara
    Merrick, Daniel T.
    MODERN PATHOLOGY, 2018, 31 : 756 - 757
  • [26] Inter-assay comparison of two PD-L1 IHC 22C3 pharmDx Assays for Dako Autostainer Link 48 (SK006) and Omnis (GE006) in different cancer types
    Kristoffersen, H. L.
    Roge, R.
    Nielsen, S.
    VIRCHOWS ARCHIV, 2024, 485 : S343 - S343
  • [27] Pitfalls of PD-L1 Immunohistochemistry: A Comparison of 22C3 and SP263 antibodies Across Laboratories and Pathologists
    Wilberger, Adam
    Aisner, Dara
    Merrick, Daniel T.
    LABORATORY INVESTIGATION, 2018, 98 : 756 - 757
  • [28] PD-L1 status in Taiwanese lung adenocarcinoma patients: Comparison of PD-L1 immunohistochemical assays using antibody clones 22C3, SP142 and SP263 with clinicopathological correlation
    Yeh, Y-C.
    Lin, S-F.
    Chiu, C-H.
    Wu, Y-C.
    Hsieh, W-Y.
    Ho, H-L.
    Chou, T-Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients
    Li, Wenbin
    Song, Peng
    Guo, Lei
    Liu, Xiuyun
    Guo, Changyuan
    Ying, Jianming
    Gao, Shugeng
    THORACIC CANCER, 2019, 10 (02) : 175 - 182
  • [30] PD-L1 IHC 22C3 pharmDx expression on cytology preparations from non-small cell lung carcinoma (NSCLC): precision and inter-observer analysis
    Musser, J.
    VIRCHOWS ARCHIV, 2019, 475 : S152 - S152